Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13984656 | 0.91 | ACHE (0.47) | — | |
| SCHEMBL13266876 | 0.77 | MAPK1 (0.52) | HRH3MAPK1MAPTALDH1A1GAA | |
| SCHEMBL13984586 | 0.75 | HIF1A (0.47) | HRH3ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL13267211 | 0.74 | KMT2A (0.60) | MAPTALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL24543121 | 0.71 | HRH3 (0.74) | HRH3MAPK1MAPTSMN1; SMN2USP2 | |
| SCHEMBL26378181 | 0.69 | HRH3 (0.74) | HRH3MAPK1MAPTALDH1A1GAA | |
| SCHEMBL14368312 | 0.69 | HRH3 (0.59) | HRH3MAPK1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13984527 | 0.69 | ACHE (0.50) | MAPK1MAPTALDH1A1GAA | |
| SCHEMBL13266944 | 0.68 | MAPK1 (0.53) | HRH3MAPK1MAPTALDH1A1GAA | |
| SCHEMBL13267168 | 0.68 | SMN1; SMN2 (0.53) | HRH3MAPK1MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | HRH3 4192/4885MAPK1 2069/4885MAPT 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.